Patient dies during Bristol Myers Squibb autoimmune CAR-T therapy trial
Bristol Myers Squibb reported a patient death in an early-stage multiple sclerosis trial involving its investigational CAR-T therapy on Friday.
Trial details and patient history
The incident occurred within a Phase 1 study designed to test the treatment for multiple sclerosis. Before receiving the experimental immunotherapy, the individual suffered from motor symptoms that standard autoimmune therapies failed to fix. Medical staff administered a strong immunosuppressant drug after these initial issues persisted without improvement.
Final medical complications and outcome
Following the administration of the CAR-T therapy, the patient developed septic pneumonia as a new complication. Bristol Myers Squibb stated that prior treatments for other health problems made it hard to identify the exact cause. The company confirmed the death in an official press release sent to reporters on Friday.
Company response regarding safety data
The biotechnology firm noted that previous complications treated before the trial injection confounded their ability to determine the root cause. This event adds to existing safety concerns surrounding the expanding field of CAR-T research. Investigators are reviewing how earlier medical interventions influenced the final outcome for this specific case.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.